Perioperatives Management der oralen Antikoagulation

Patienten mit oraler Antikoagulation stellen besondere Anforderungen an das perioperative Management: Sowohl das Blutungs- als auch das Thromboserisiko sind erhöht. Zudem werden pharmakologisch sehr unterschiedliche Medikamente eingesetzt. Ein standardisiertes Vorgehen erhöht die Patientensicherheit und bietet logistische Vorteile. Gleichzeitig müssen individuelle Risikofaktoren im Blick behalten werden, um Patienten mit oraler Antikoagulation optimal zu versorgen.

• Literatur

• 1 Healey JS, Eikelboom J, Douketis J. et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012; 126: 343-348
• 2 Douketis JD, Spyropoulos AC, Duncan J. et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med 2019; 179: 1469-1478
• 3 Godier A, Martin AC, Leblanc I. et al. Peri-procedural management of dabigatran and rivaroxaban: Duration of anticoagulant discontinuation and drug concentrations. Thromb Res 2015; 136: 763-768
• 4 Borges NM, Thachil J. The relevance of the coagulation screen before surgery. Br J Hosp Med (Lond) 2017; 78: 566-570
• 5 Samuelson BT, Cuker A. Measurement and reversal of the direct oral anticoagulants. Blood Rev 2017; 31: 77-84
• 6 Douketis JD, Spyropoulos AC, Kaatz S. et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med 2015; 373: 823-833
• 7 Steffel J, Collins R, Antz M. et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace 2021; 23: 1612-1676
• 8 Lock JF, Ungeheuer L, Borst P. et al. Markedly increased risk of postoperative bleeding complications during perioperative bridging anticoagulation in general and visceral surgery. Perioper Med (Lond) 2020; 9: 39
• 9 Douketis JD, Spyropoulos AC, Murad MH. et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest 2022; 162: e207-e243
• 10 Nast A, Ernst H, Rosumeck S. et al. Risk of complications due to anticoagulation during dermatosurgical procedures: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2014; 28: 1603-1609
• 11 Birnie DH, Healey JS, Wells GA. et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013; 368: 2084-2093
• 12 Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89: 635-641
• 13 Martin KA, Beyer-Westendorf J, Davidson BL. et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost 2021; 19: 1874-1882
• 14 Johansen KB, Balchen T. Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?. Exp Hematol Oncol 2013; 2: 21
• 15 Douxfils J, Adcock DM, Bates SM. et al. 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost 2021; 121: 1008-1020
• 16 Gómez-Outes A, Alcubilla P, Calvo-Rojas G. et al. Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants. J Am Coll Cardiol 2021; 77: 2987-3001
• 17 Benz AP, Xu L, Eikelboom JW. et al. Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban. Thromb Haemost 2022; 122: 998-1005